DUBLIN–(BUSINESS WIRE)–The “Understanding Active Pharmaceutical Ingredients (APIs) Training Course (Apr 29th – Apr 30th, 2026)” training has been added to ResearchAndMarketsDUBLIN–(BUSINESS WIRE)–The “Understanding Active Pharmaceutical Ingredients (APIs) Training Course (Apr 29th – Apr 30th, 2026)” training has been added to ResearchAndMarkets

Understanding Active Pharmaceutical Ingredients (APIs): Online Training Course (Apr 29-30, 2026) – Enhance Your API Expertise with In-Depth GMP and GDP Training – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Understanding Active Pharmaceutical Ingredients (APIs) Training Course (Apr 29th – Apr 30th, 2026)” training has been added to ResearchAndMarkets.com’s offering.

An active pharmaceutical ingredient (API) or drug substance is any substance or mixture of substances intended to be used in the manufacture of a medicinal product, which is intended to furnish pharmacological activity, or have another direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or affect the structure and function of the body.

This course has been designed to provide attendees with a fundamental understanding of best practice and the regulatory environment applicable to active pharmaceutical ingredients in the pharmaceutical industry. It will cover key terminology, the EU and USA regulatory framework, Good Manufacturing Practice (GMP) requirements including controls and validation, and consider Good Distribution Practice (GDP) and how to manage your supply chain. Practical exercises will form part of the course to aid the learning process.

This is an essential and valuable introduction to the manufacture of APIs.

Benefits of Attending:

  • Gain a comprehensive overview of the API regulatory framework
  • Enhance your understanding of the key terms used in API manufacture
  • Recognise how Good Manufacturing Practices (GMP) apply to API synthesis
  • Understand the different approaches between small-molecule and large molecule processing
  • Learn how to manage the risk associated with your supply chain

Who Should Attend:

  • New entrants to those individuals working in a GxP environment
  • Quality management manufacturing specialists
  • Regulatory compliance specialists
  • Pharmaceutical technical professionals
  • Pharmaceutical professionals looking to enhance their Continuous Professional Development (CPD)

Agenda: Day 1

Introduction to APIs

  • Terminology and acronyms
  • Globalisation
  • Introduction to the regulatory framework

Methods and equipment – Part 1

  • Chemical synthesis
  • Reactors
  • Isolation
  • Drying
  • Exercise: managing particle size

Methods and equipment – Part 2

  • Biological
  • Fermentation
  • Harvesting
  • Exercise: impurities

Good Manufacturing Practice (GMP)

  • Requirements
  • Regulations
  • EU
  • FDA
  • Exercise: similarities and differences

GMP requirements (continued)

  • Pharmaceutical Quality System
  • Validation and Qualification
  • Outsourcing
  • Exercise: specialist or generalist

Supply chain considerations

  • Falsified Medicines Directive (FMD)
  • Good Distribution Practice (GDP) for APIs
  • Exercise risk mitigation

Agenda: Day 2

Introduction and recap

Registration aspects of production and control

  • The registration process
  • The Common Technical Document (CTD)
  • Active substance/drug master files
  • Exercise: strategy

Laboratory controls

  • Good Quality Control Laboratory Practice (GQCLP)
  • Validation
  • Stability
  • Exercise: data Integrity

Process validation

  • Purpose of validation
  • General considerations
  • Exercise: critical attributes

Cleaning validation

  • Cleaning strategy
  • Key requirements
  • Residues
  • Exercise: purpose

API control packaging materials

  • What to consider
  • Data requirements
  • Extraction, interaction, migration and sorption
  • Toxicology
  • Exercise: environmental factors

Wrap up and Q&A

For more information about this training visit https://www.researchandmarkets.com/r/ydcok1

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
aPriori Logo
aPriori Price(APR)
$0,09878
$0,09878$0,09878
-4,34%
USD
aPriori (APR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Spot silver falls below the $100 mark

Spot silver falls below the $100 mark

PANews reported on January 30 that, according to Jinshi, some trading platforms showed that spot silver fell below the $100 mark, plunging by about $15 during the
Share
PANews2026/01/30 17:34
Solana network saw its active addresses more than double to over 5 million in January, with daily transaction volume jumping to 87 million.

Solana network saw its active addresses more than double to over 5 million in January, with daily transaction volume jumping to 87 million.

PANews reported on January 30th that, according to Nansen's monitoring, Solana's performance in the first 30 days of 2026 is as follows: The number of active addresses
Share
PANews2026/01/30 17:15
Australian regulators ease regulations on stablecoin intermediaries

Australian regulators ease regulations on stablecoin intermediaries

PANews reported on September 18th that, according to Decrypt, the Australian Securities and Investments Commission (ASIC) has granted a regulatory exemption to stablecoin intermediaries, allowing them to distribute cryptocurrencies issued by licensed Australian institutions without having to hold a separate financial services license. The exemption, published Thursday, states that intermediaries distributing stablecoins issued by Australian Financial Services (AFS) licensed issuers no longer need to apply for separate AFS, market, or clearing facility licenses. This measure, effective upon registration of federal legislation, is a significant step forward in addressing Australia's regulatory challenges in the stablecoin market. Blockchain APAC CEO Steve Vallas stated that this move is a temporary transition before broader reforms and is consistent with financial services law. The exemption does not change the determination of whether stablecoins are financial products, but simply "suspends the secondary licensing requirement for distributors of licensed issuers," allowing distribution through licensed channels while maintaining issuer liability and requiring intermediaries to provide product disclosure statements to ensure transparency.
Share
PANews2025/09/18 13:25